PERSONALIZED MEDICINE:

OPPORTUNITIES IN QUÉBEC

Marc LePage, President and CEO, Génome Québec

EuroBioForum 2nd Annual Conference 2013

May 28, 2013

Munich, Germany

1- Génome Québec in brief

2- Platforms

3- Personalized medicine portfolio

4- What do we offer?

5- What are we looking for?

6- Personalized medicine projects (4-minute video)

OUTLINES

May 28, 2013 2 Marc LePage, President and CEO

Launched in 2000

Large-scale genomics research

$750 million invested / 80 projects

Health, Forestry, Agriculture, Environment, etc.

Operates genomics platform

750 researchers at all major universities

90 employees

GÉNOME QUÉBEC IN BRIEF

May 28, 2013 3 Marc LePage, President and CEO

May 28, 2013 4

McGILL UNIVERSITY AND GÉNOME QUÉBEC

INNOVATION CENTRE

175 employees:

110 McGill (research): 15 research teams

65 Génome Québec (management of services): average

experience of GQ team > 4.5 years

Number of users: > 800 research teams

Annual revenues: $12 million

Marc LePage, President and CEO

May 28, 2013 5

TECHNOLOGIES AND APPLICATIONS

Whole genome sequencing

Exome sequencing (custom capture)

RNA-Seq

ChIP-Seq

Epigenetics , methylation

Transcriptomics, expression

Genotyping (GWAS and custom)

Validation (low throughput sequencing and genotyping)

Bioinformatics

Data analysis

Marc LePage, President and CEO

May 28, 2013 6

INNOVATION CENTRE TODAY

52%33%

15%

Geographical distribution of revenues of the Innovation Centre for 2011-2012

Québec

Rest of Canada

International

Marc LePage, President and CEO

May 28, 2013 7

INTERNATIONAL DISTRIBUTION OF USERS

23 countries (2011-2012)

Mostly in Europe!

Marc LePage, President and CEO

May 28, 2013 8

COGS

MAJOR CANADA/EUROPAN UNION COLLABORATION

Marc LePage, President and CEO

May 28, 2013 9

INNOVATION CENTRE AND EUROPEAN UNION

Citation

“I am heading one of the largest genotype projects globally and

a large part of our nearly 250,000 samples have been

genotyped at the McGill University and Génome Québec

Innovation Centre. We are very impressed with the expertise

and professionalism of the personnel, their project management

approach and the capacity to deliver large-scale projects in a

timely manner with very high quality standards.”

Per Hall, MD, PhD; Medical Epidemiology and Biostatistics,

Karolinska Institute,and Head of the COGS International Consortium

Marc LePage, President and CEO

May 28, 2013 10

PERSONALIZED MEDICINE PORTFOLIO

Principal

Investigator Institution Project Title

Total Budget

($)

Patrick Cossette Centre hospitalier universitaire de

l’Université de Montréal (CHUM) Personalized medicine in the treatment of epilepsy 10,833,759

Nada Jabado Research Institute of the

McGill University Health Centre

Biomarkers for pediatric glioblastoma through

genomics and epigenomics 5,074,844

Claude Perreault

Hôpital Maisonneuve-Rosemont

and the Institute for Research in

Immunology and Cancer of

Université de Montréal

Personalized cancer immunotherapy 13,486,784

John D. Rioux Montreal Heart Institute of

Université de Montréal

Inflammatory bowel diseases Genomic Medicine

Consortium (iGenoMed) 9,892,162

François Rousseau Université Laval and

CHU de Québec

Personalized genomics for prenatal aneuploidy

screening using maternal blood (PEGASUS) 10,459,731

Guy Sauvageau

Institute for Research in

Immunology and Cancer of

Université de Montréal

Innovative chemo-genomic tools to improve clinical

outcome in acute myeloid leukemia 11,325,631

Jacques Simard Université Laval and

CHU de Québec

Personalized risk stratification for the prevention and

early detection of breast cancer 11,382,455

Jean-Claude Tardif Montreal Heart Institute of

Université de Montréal

Personalized medicine strategies for molecular

diagnostics and targeted therapeutics of cardiovascular

diseases

9,443,002

4 collaborations

6,666,950

Marc LePage, President and CEO

May 28, 2013 11

WHAT DO WE OFFER?

International collaborations

Access to genomics platform (sequencing, genotyping)

CARTaGENE/Genizon: Population cohorts of Québec

« Colloque sur la médecine personnalisée: Parce que les

solutions sont dans nos gènes »

Investigators and health policy meeting that will be held

October 1, 2013, in Québec City

Marc LePage, President and CEO

May 28, 2013 12

WHAT DO WE WANT?

Today

Translational strategies: successful models and approaches

Collaborators, cohorts

Tomorrow

Clinical genomics: lessons learned

Genomics and prevention (healthy lifestyle habits…)

Marc LePage, President and CEO

May 28, 2013 13

PERSONALIZED MEDICINE PROJECTS

Marc LePage, President and CEO